AZAleksander A. Zavyalov

Aleksander A. Zavyalov

*This is an algorithmically generated author record based on publicly available information.

Aleksander A. Zavyalov has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and Economic Considerations of CT Coronary Calcium Screening and Its Role in Integrated BIG 3 Preventive Strategies

    by Dmitry A. Andreev, Aleksander A. Zavyalov

    Introduction . Asymptomatic individuals account for almost 34% of all atherosclerosis-related deaths. Prognostic data says that cardiovascular diseases, chronic obstructive pulmonary disease, and lung cancer will continue to dominate the overall structure of causes of death until 2050. These conditions form the Big-3 Group, imposing a significant socioeconomic burden on the healthcare systems of most countries. CT-based methods enable the diagnosis of Big-3 diseases at the latent stage. It is suggested that single screening for multiple diseases (Big-3 screening) performed within one chest CT scan session improves the efficiency of examination at minimal additional cost. The economic potential of Big-3 screening has been demonstrated in early-stage technology assessments. Materials and methods . The authors analyzed CT innovations for coronary calcium scans, current AI-driven approaches to integrating combined protocols for CT imaging, and clinical effectiveness and cost-effectiveness of implementing these tools. Results . Advanced technology, such as dual-source computed tomography (DSCT) and photon-counting computed tomography (PCCT), showed a high reproducibility of coronary calcium screening results. These techniques allow the reliable evaluation of calcium score using the protocol for non-ECG-gated low-dose computed tomography (LDCT). Medical centers not equipped with high-resolution CT scanners can use AI algorithms instead. Such algorithms enhance the automatic grading of coronary calcium severity while also assessing the quality of images, validating the reliability of results, and making decisions on next steps in the patient journey, including further standard imaging tests. Conclusion . The optimization of protocols for CT screening, as well as patient inclusion and exclusion criteria, must be guided by the results of clinical trials and mathematical modeling. This will balance clinical and economic benefits against iatrogenic risks, thereby establishing the feasibility of coronary artery calcium screening within BIG-3-type strategies.

  • STAS — the fourth mechanism of invasion of malignant lung tumors. Impact on treatment outcomes

    by G.A. Baksiyan, A.A. Zavialov, S.E. Voskanyan, S.V. Lishuk

    In the world literature, there has been increased interest in the little-studied mechanism of invasion of malignant lung tumors, officially recognized by the WHO only in 2015. This route of invasion was called STAS (spread through air spaces). It has now been proven that STAS significantly worsens the course of malignant lung tumors and correlates with the rate of local relapses after surgical treatment, especially when performing sublobar resections. This article covers the current state of the problem associated with relapses after surgical treatment of malignant (primary and secondary) lung tumors caused by the presence of the STAS invasion component in tumors. The study of the STAS phenomenon will complement the complex picture of carcinogenesis in lung tissue and will allow a more conscious approach to the issue of surgical treatment of malignant lung pathology, including in the sublobar variant.


  • Benign metastasic pulmonary leiomyoma

    by G. A. Baksiyan, A. A. Zavialov

    Benign metastatic leiomyoma is a rare lung tumor. There are just over 200 cases of this disease reported in the global literature.This article presents a clinical observation by the authors, describing a case of multiple leiomyomas located in the lungs of a young woman who had previously undergone a supravaginal hysterectomy due to a similar tumor.Case Description: Patient R., 42 years old. Five years ago, the patient underwent surgical treatment in the form of a supravaginal hysterectomy for myoma. There was no history of malignant diseases. During a routine examination, computed tomography of the chest revealed multiple solid lesions in the lungs. Comprehensive examinations, including esophagogastroscopy, fiber colonoscopy, fiber bronchoscopy, and positron emission tomography, did not reveal other tumor pathologies (besides the lung lesions). For morphological study of the tumor foci, a thoracoscopic atypical resection of the lower lobe of the left lung was performed. Histological conclusion: benign metastatic leiomyoma of the lung. No malignant tumor growth was found in the examined material.Conclusion: Benign metastatic pulmonary leiomyoma is a rare tumor that lacks distinct criteria for reliable preoperative differential diagnosis. Benign metastatic leiomyomas occur predominantly in women with uterine leiomyoma, especially after surgical treatment for this pathology, although isolated cases of this disease in men have been reported. Typically, multiple solid foci are detected in the lungs during radiological examination.

  • Open Access

    Primary Cutaneous Diffuse Large B‑Cell Lymphoma, Leg Type: A Clinical Case

    by G. E. Zimnikov, A. V. Aksenenko, A. A. Zavialov

    Introduction. Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type it is a rare variant of skin lymphoma that has an aggressive course and a high risk of extracutaneous manifestations.The purpose of this work is to familiarize a wide range of specialists with the clinical manifestations of a rare disease — primary cutaneous diffuse large B-cell lymphoma.Materials and methods. An interesting clinical case is presented and the medical history of a patient with B-cell lymphoma from the skin is analyzed.Results. A differential diagnosis of the disease was made. Based on the study of histological material, the final clinical diagnosis was established and further treatment tactics were determined.Discussion. The patient had spots and plaques on the lower extremities, the sole visible signs of the disease. These symptoms may suggest a positive prognosis and a gradual progression. Diagnostic measures should include gathering medical history, assessing the local condition, and carrying out an excision biopsy early in the examination process for an accurate and prompt diagnosisConclusion. Due to the rarity of this subtype of lymphoma and the limited number of domestic publications on the topic, a more detailed study and description of individual clinical cases can lead to a better understanding of the characteristics of the symptoms and the processes of pathological changes in cells, tissues, and organs. This could potentially lead to the development of more efficient methods for early diagnosis and timely treatment of the condition.

  • The concept of developing and integrating the virtual Cancer center for outpatient services into existing primary care units

    by Дмитрий Анатольевич Андреев, Aleksander A. Zavyalov

    Introduction. The key functional objectives of the Outpatient (Ambulatory) Cancer Care Center (OCCC) are: the improvement the accessibility and quality of medical care for patients in whom a tumor process is suspected, and for patients with an established diagnosis of malignant neoplasm. OCCC solves important problems in ensuring complete, timely diagnosis, and early beginning of the treatment. The finding optimal ways to manage the work in the OCCC will help achieve the key indicators of the capital’s regional project “Fighting Cancer.” Purpose of the study. Description of a possible option for the formation of a virtual digital Cancer Center for outpatient care operating on the basis of conventional polyclinics and hospitals without placing forces and means of oncological care (primary care) in separate buildings by combining oncological and regular medical care provided for a unified patients flow. Results. The concept of managing virtual digital OCCC has been developed. That concept can be realized through wide teaching (initially or later on) and granting the additional (second / double specialty) medical specialization in “oncology” to the physicians working in ordinary clinics / hospitals. Some types of highly specialized anticancer treatment (radiotherapy, complex/combined procedures) will continue to be provided centrally in individual medical centers / departments at other levels. Materials and methods. This research study is based on results obtained through searching the relevant sources in the Google system and elibrary.ru (RSCI database). We analyzed the results published over 2021–2022. Research limitations. Despite the obviousness of some prospects for managing a virtual OCCC, this concept requires testing in pilot studies, with their implementation in real clinical practice. Conclusions. If positive results are obtained and confirmed, this approach may become more widespread in the oncological service.

  • Open Access

    Effect of antitumor therapy on microflora and oral mucosa in patients with malignant neoplasms

    by Natal’jA A. Pashchenko, Vladimir F. Kazakov, Aleksander A. Zavyalov, Valentina N. Olesova, Aleksandr I. Tyryshkin

    The present article investigates the relationship between the microbiota of the oral cavity and oral mucositis induced by systemic antitumor therapy in patients with malignant neoplasms. This article highlights modern ideas about the composition of the normal microbiota of the oral cavity and its changes during chemotherapeutic treatment. It has been shown that the normal oral microbiota includes representatives of such genera as Actinomyces, Corynebacterium, Fusobacterium, Leptotrichia, Neisseria, Prevotella, Streptococcus, and Veillonella. Moreover, it is emphasized that despite the existence of modern molecular genetic techniques and development of an oral microbiota database, determining the role of individual taxonomic units in oral homeostasis remains challenging. Existing studies of changes in the qualitative and quantitative composition of oral microflora against the background of drug antitumor therapy have demonstrated that treatment is associated with significant changes in the microbiological landscape of the oral cavity. An increase was noted in the number of Gram-negative anaerobic opportunistic flora and a decrease in the representation of protective commensal flora. It has been demonstrated that the components of a bacterial cell can modulate the local reactions of a macroorganism through a system of Toll-like receptors while acting in different directions. Several unresolved fundamental issues related to the role of oral microbiota in the pathogenesis of oral mucositis are highlighted.

  • Open Access

    The place and role of oral microflora in the pathogenesis of oral mucositis in malignant neoplasms (literature review)

    by Aleksander A. Zavyalov, Aleksandr I. Tyryshkin, Valentina N. Olesova, Nataliya A. Pashchenko, Marina M. Gurkova, Пащенко Наталья Александровна

    Background. Oral mucositis (OM) is one of the most frequent complications of systemic drug therapy of oncological diseases. Clinically, the disease manifests itself in the form of erythema and ulceration of the non-corneating mucous membrane. Although this condition is self-healing, it can affect the conduct of comprehensive antitumor treatment. Currently, the pathophysiological model of the development of OM is supplemented with new data obtained during studies of the oral microflora. Antitumor treatment can lead to changes in the composition of the resident oral microflora and it is quite possible that the changes that occur may affect the development of damage to the oral mucosa. The expansion of knowledge in this area allows researchers to look for new ways to include oral microbiota in OM management strategies. Aim. To summarize and update the accumulated data regarding the role of the oral microbiota in the pathogenesis of OM in patients with malignant neoplasms. Materials and methods. Literature search was performed in Medline, Cochrane Library, Elibrary and Pubmed, including publications demonstrating the current ability to assess the impact of the oral microbiome on OM, as well as developments in this area relating to OM management. Results. In the review the current views on the position of the oral microbiome in the pathogenesis of OM were highlighted and the promising directions for the use of agents influencing the state of the oral microbiota in various strategies to control this disease were emphasised. Conclusion. A better understanding of the pathogenesis of OM and the inclusion of new factors, such as the oral microbiome, into the picture of pathogenesis is likely to enable the formation of more effective management strategies for this disease in the future. This direction seems very promising, and developments in this area show promising results.


  • Open Access

    Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress – June 2022

    by Dmitry A. Andreev, Aleksander A. Zavyalov

    In the structure of the incidence of skin tumors, melanoma accounts for a relatively smaller percentage, but that disease is associated with higher risk of an adverse outcome compared with many other malignancies. The study of innovative clinical developments in drug therapy for resectable melanoma, presented at the American Society of Clinical Oncology Annual Meeting June 2022. The best clinical developments in drug treatment of patients with resectable melanoma were selected for analysis: 1) phase 3 study KEYNOTE-716; 2) PRADO; 3) Neo Trio; 4) SWOG 1512. The presented developments bring extremely promising results for melanoma therapy workflows. The use of cutting-edge anti-cancer therapeutics acting on various molecular targets drastically improves the tumor response as well as straitens the appearance of treatment-related adverse events.

  • New clinical developments in combination therapy for metastatic melanoma: ASCO annual congress, June 2022

    by A.A. Zavyalov, D.A. Andreev

    Introduction. In the morbidity patterns of skin tumors, melanoma accounts for a relatively smaller percentage but is associated with a very high risk of an adverse outcome. The mortality rate of patients during the year since the diagnosis of melanoma in the Russian Federation in 2019 was 9.5%. The development and implementation of effective methods for melanoma treatment continue. Objective. To review advanced clinical developments for the drug therapy of metastatic melanoma, presented at the annual ASCO congress in June 2022. Materials and methods. We searched the PubMed/Medline, MEDtalks.nl and Google databases with keywords «melanoma», «metastatic», «clinical trials», «ASCO», «2022», etc. Data sources in Dutch and English were selected. Results. The world is actively discussing the results of the annual ASCO Congress in June 2022, including the results of the most advanced research in the field of metastatic melanoma therapy: 1) RELATIVITY-047; 2) Tricotel phase 2 study; 3) interim results of a randomized, controlled phase 2 study of efficacy and safety of the combination of toripalimab (anti-PD-1 antibodies) and axitinib versus toripalimab or axitinib monotherapy in treatment-naïve patients with unresectable or metastatic mucosal melanoma; 4) phase 2 trials of efficacy and safety of camrelizumab (anti-PD-1 IgG4 antibodies) in combination with apatinib (VEGFR-2 tyrosine kinase inhibitor) and temozolomide in the first-line therapy in patients with advanced acral melanoma. Discussion. The results of the reviewed clinical developments demonstrate promising effects and an acceptable drug safety profile of combination therapy for metastatic melanoma. New targeted agents with different molecular targets can dramatically improve the rates of relapse-free and overall survival of patients and reduce the severity of the effect of melanoma escaping from the drug response.

  • Open Access

    Factors of Organizing Surgical Treatment of Upper Gastrointestinal Cancers and Patient Survival: Real-World Data

    by D. A. Andreev, A. A. Zavyalov

    Aim: to analyze the safety and effectiveness of the method of cold snaring resection with preliminary hydropreparation when removing superficially colorectal epithelial neoplasms with a diameter of 5 to 25 mm.Material and methods. The number of complications and disease recurrence after endoscopic excisions by “cold” snaring resection with preliminary hydropreparation of superficially neoplasms with a diameter of 5 to 25 mm was assessed.Results. Neoplasms were removed in a single block in 89/122 (72.95 %) cases. Neoplasms with a diameter of 5 to 9 mm were excisions in a single block in 100 % of cases, with a diameter of 9 to 14 mm in 28/30 (93.33 %) cases, with a diameter of 15 to 19 mm in 12/38 (31.57 %) cases. According to the results of a lifetime pathoanatomic examination of the removed material, serrated dysplasia (serrated dysplasia, low grade) was detected in 76 cases; micro vesicular hyperplastic polyps (Hyperplastic polyp, micro vesicular type MVHP) were established in 9 cases; hyperplastic polyps containing goblet cells (Hyperplastic polyp, goblet cell GCHP) were in 5 cases; tubular adenoma with dysplasia (Tubular adenoma, low grade) was in 32 cases. Delayed bleeding and perforation of the intestinal wall, both at the time of resection, and in the delayed period was not observed. No local recurrence was detected in the groups of patients with neoplasms diameters of 5-9 and 10-14 mm. One case of local recurrence was detected in a group of patients with a neoplasms diameter from 15 to 19 mm (1/38 = 2.63 %) and one case in a group with a neoplasms diameter of 20-25 mm (1/5 = 20 %).Conclusions. Cold endoscopic snaring resection of colorectal epithelial neoplasms with preliminary hydropreparation in the submucosa is a safe and effective method of excisions superficially epithelial neoplasms of the colon with a diameter of 5 to 19 mm.